Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606814 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by Infinity Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 8
- Study locations
NCT00606814: Completed Phase 1 study of Solid Tumors, sponsored by Infinity Pharmaceuticals.
NCT00606814 is a Phase 1 study of Solid Tumors that has completed, run by Infinity Pharmaceuticals. The registered enrollment target is 60 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (79% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00606814, a Phase 1 study of Solid Tumors, has completed, sponsored by Infinity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study is a Phase I clinical trial of IPI-504 in combination with docetaxel (Taxotere).The purposes of the study are to determine: * the safety profile, * the highest dose of IPI-504 that can be given with docetaxel without causing severe side effects, and * to recommend a Phase II dose of the combination in patients with solid tumors.
Conditions Studied
Interventions
- DRUG IPI-504, docetaxel
Study Locations (8)
New York
- Roswell Park Cancer Institute - Buffalo
- Memorial Sloan-Kettering Cancer Center - New York
Ohio
- Gabrail Cancer Center - Canton
- Gabrail Cancer Center - Dover
Arizona
- TGen Clinical Research in Scottsdale - Scottsdale
Connecticut
- Yale Cancer Center - New Haven
Florida
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
What the finished NCT00606814 record still lists
NCT00606814 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which IPI-504, docetaxel is the first listed.
NCT00606814 lists 8 locations in 6 states (New York, Ohio, Arizona).
Frequently Asked Questions
What is clinical trial NCT00606814 about?
NCT00606814 is a clinical study titled "Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors". This study is a Phase I clinical trial of IPI-504 in combination with docetaxel (Taxotere).The purposes of the study are to determine: * the safety profile, * the highest dose of IPI-504 that can be given with docetaxel without causing severe side effects, and * to recommend a Phase II dose of the ...
What is the current status of trial NCT00606814?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2007-12. Estimated completion is 2011-12.
What conditions does trial NCT00606814 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT00606814?
The interventions under investigation include: IPI-504, docetaxel (DRUG).
Who is sponsoring clinical trial NCT00606814?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00606814 being conducted?
This trial has 8 study locations across Arizona, Connecticut, Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00606814's enrollment target sits among peer trials
60 74th of 125 higher than 51 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia